The primary object of the DEPOSITION study is to determine in patients undergoing on-pump cardiac surgery, if topical tranexamic acid (intra-pericardial) is superior to the usual intravenous tranexamic acid administration for reducing the risk of in-hospital red blood cell transfusion or seizure. We are proposing a multi-centre double-blinded randomized control trial including 3800 cardiac surgery patients to compare the effect of IV TxA with topical TxA on the proportion of patients requiring RBC transfusion.

We are starting with 500 participants at the Hamilton General Hospital with the PHRI internal funding grant. We successfully completed the DEPOSITION pilot study which included 107 cardiac surgery patients and proved feasibility of our proposed protocol. Subjects will be randomized in a 1:1 ratio to topical TxA (IV placebo + topical TxA) or intravenous TxA (IV TxA + topical placebo). The surgeons, anesthetists, along with research and clinical teams are blinded to the allocation. Patients will be followed in hospital until discharge or 10 days (whichever comes first).

Our vision is to produce strong evidence to support practice change in cardiac surgery toward the use of topical TxA.

DEPOSITION Slides - Download PDF
Study Type

Inteventional - Drug

Study Design

Double-dummy RCT

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2019 - 2023



Canadian Institutes of Health Research (CIHR)

McMaster MSA 2019-20 grant

PHRI internal grant

Back To Top